Anti-Obesity Medicines: How Medical Weight Management Works

• Explains what anti-obesity medication means as a clinical term, and what the AOM abbreviation stands for.
• Answers the first line question properly, using what NICE actually says about where medicines sit.
• Sets out the review points and stopping rules built into this treatment, which most patients are never told about.
• Online consultation with UK registered prescribers, from a GPhC registered pharmacy, if you want your options reviewed clinically.

Anti-obesity medication is prescribed alongside a reduced calorie diet and increased physical activity, not instead of them. That is the single most important thing to understand about how this treatment works, and it is written into UK guidance.

The name matters too. These are medicines for a clinical condition, prescribed against clinical criteria, reviewed at fixed points and stopped if they are not working. That is a very different thing from weight loss medicines, and the difference shapes everything from who is eligible to what happens after a year.

This page explains the term, answers the first line question properly, and sets out what medical weight management actually involves.

Key things to know

• Anti-obesity medication, often shortened to AOM, means a medicine licensed to treat obesity and overweight, prescribed alongside diet and activity changes.
• NICE positions these medicines after dietary, exercise and behavioural approaches have been started and evaluated. The first line treatment for obesity is not a medicine.
• There is no single first line anti-obesity medicine. NICE presents the options rather than ranking them, and selection is individual.
• Five active ingredients are licensed for weight management in the UK, across four drug classes.
• Almost nothing is available over the counter. The one exception is a lower strength orlistat, which is a pharmacy medicine sold after a pharmacist assessment.
• These treatments have review points built in. If an agreed percentage of body weight has not been lost by a set point, treatment is stopped.
• Obesity is treated as a long term condition. Weight regain after stopping is common, which is why this is ongoing management rather than a course.
• Obesity is a chronic disease, and it affects more than 40% of men aged 18 and over in the U.S.

What are anti-obesity and weight loss medications?

Anti-obesity medication means a prescription medicine used in obesity treatment or weight loss treatment for overweight and obesity, licensed specifically to treat obesity or overweight with a related health condition, and used as an addition to a reduced calorie diet and increased physical activity.

Three parts of that definition do real work. Licensed specifically rules out medicines used off licence and everything sold as a supplement. Obesity or overweight with a related condition means eligibility runs on clinical criteria, not on how you feel about your weight. And as an addition to means the medicine is never the whole treatment.

NICE states directly that all medicines for weight management should be used alongside a reduced calorie diet and increased physical activity. That is not a disclaimer attached to the prescription. It is part of how the medicine is licensed and how it was tested.

What does AOM stand for?

AOM stands for anti-obesity medication, sometimes written anti-obesity medicine. It is the abbreviation clinicians and researchers use, and you will see it in guidance documents and studies more often than in conversation with a patient.

It covers the whole category rather than any one drug. When a clinical document refers to AOMs, it means the licensed medicines for weight management as a group, in the same way that antihypertensives means the group of blood pressure medicines.

Using the term is a useful signal in itself. It frames obesity as a condition being treated, which is how UK guidance approaches it.

What is the first line treatment for obesity?

The first line treatment for obesity is not a medicine. NICE states that the first-line approach involves healthy eating, physical activity, behavioural support, and broader lifestyle changes or lifestyle modification before medicines are added for men aged 18 and over living with overweight or obesity.

So the sequence is: a multicomponent approach covering diet, physical activity and behaviour comes first, it is given time and then assessed, and medicines are added if that has not been enough. NICE also says the decision to start a medicine should follow a discussion with the person, including a discussion of the potential impact on their motivation.

That last point is easy to skim past and worth pausing on. Guidance explicitly asks prescribers to consider whether adding a medicine might undermine someone's own efforts, which tells you how seriously the adjunct framing is meant.

Is there a first line anti-obesity medicine?

No, not in the sense of one medicine that everyone is offered first. NICE presents the licensed medicines as a set of options rather than a ranked sequence, and which one is appropriate depends on the individual.

The factors that drive that decision include your BMI (body mass index), which weight related conditions you have, your full medical history, every other medicine you take, whether you are able to self inject, and what you are able to sustain. Eligibility for prescription weight loss medications commonly starts at a BMI of 30 or above, subject to clinical assessment and other health factors. Two people with identical BMIs can appropriately be offered different treatments.

Treatment suitability depends on an individual clinical assessment. Your prescriber will determine the appropriate treatment, and these medicines should only be used under the supervision of an appropriately qualified prescriber.

Anyone telling you there is a single best anti-obesity medicine is not describing how prescribing works.

What anti-obesity medicines are licensed in the UK?

Five active ingredients hold MHRA licences for weight management in men aged 18 and over, covering licensed anti-obesity prescription medications used for chronic weight management and weight reduction long term across four drug classes.

GLP-1 receptor agonists were initially developed for type 2 diabetes.

In the U.S., fda approved options for long-term use include orlistat and semaglutide, and semaglutide was approved there for obesity treatment in 2021.

Tirzepatide was licensed by the MHRA for weight management in men aged 18 and over aged 18 and over in November 2023. On 11 June 2026 the MHRA approved an oral semaglutide tablet, the first GLP-1 receptor agonist in tablet form licensed in the UK for this use.

A small number of specialist prescription drugs exist for obesity linked to rare genetic disorders, prescribed within specialist services after genetic testing. Those sit outside general weight management.

In other markets, phentermine topiramate is also among fda approved obesity medications, combining an appetite suppressant with a medicine that increases feelings of fullness.

How medical weight management actually works

Medical weight management is a process with defined stages, not a prescription handed over once. Understanding the stages tells you what to expect and what your prescriber is looking for.

Assessment comes first

Before anything is prescribed, an assessment by healthcare professionals or a health care professional establishes whether prescription weight loss is appropriate. It covers your BMI and any weight related health conditions, your medical history, every medicine you currently take, pregnancy status, and previous attempts at weight management.

Eligibility runs on BMI thresholds combined with weight related conditions, with lower thresholds applying to some ethnic groups who face higher weight related health risk at a given BMI. Some medicines are also licensed for pediatric patients aged 12 and over with obesity, typically where BMI is at or above the 95th percentile.

Some people are assessed and found not to be suitable. That is the process working as intended, and it is the main practical difference between a regulated service and a site that takes payment from everyone.

Starting treatment is deliberately slow

Most of these medicines are started at a lower dose and increased in steps, with a minimum period at each level, specifically to reduce side effects. Reaching a full dose takes months. This stepped approach helps regulate appetite while improving tolerability, and gastrointestinal side effects with medicines such as tirzepatide can affect up to 70% of users.

This is why nothing in this area is fast, and why judging a treatment in the first few weeks tells you very little. The early period is about tolerating the medicine rather than measuring what it does.

Alongside this, the diet and activity component continues. The medicine makes eating less easier. It does not decide what you eat.

Review points and stopping rules

This is the defining feature of anti-obesity prescribing, and most people are never told about it before they start.

These treatments have review points built in, with a percentage of body weight attached. If you have not lost an agreed proportion of your starting body weight by a set point, the medicine is stopped. For liraglutide, guidance is that treatment should be stopped after twelve weeks at the maintenance dose if at least 5% of initial body weight has not been lost. These checkpoints are used to assess whether patients lose enough weight relative to their starting body weight to justify continuing treatment.

NICE publishes a specific resource for prescribers covering how to assess, prescribe, monitor and stop medicines for weight management. The inclusion of stopping in that list is deliberate. It is a standard part of the treatment, not a failure.

The practical consequence is worth planning for. You are being offered a trial with a checkpoint rather than an open ended prescription, and if the medicine has not produced a meaningful result by that checkpoint, continuing is unlikely to help.

Ongoing monitoring

If treatment continues, so does review. Ongoing monitoring supports weight loss maintenance, not just short-term loss, and covers weight and waist measurement, side effects, blood pressure where relevant, and whether the diet and activity components are still in place.

The last of those is the one people underestimate. If the behavioural side has quietly stopped while the medicine continues, the result at twelve months looks very different, and so does what happens if the medicine is ever stopped. Follow-up also tracks practical changes people notice, such as better energy, improved sleep, and reduced joint pain as body fat and excess body weight come down.

What medical weight management includes beyond the prescription

The medicine is one component of medical weight management, and on its own it is the weakest version of the treatment.

A proper service wraps four things around the prescription. The first is the dietary component, which should be a specific healthy diet or balanced diet you can realistically follow rather than a general instruction to eat less. For some people, that may be structured as a healthy eating plan or low calorie diet, depending on the treatment plan. Protein intake matters more here than most people expect, because appetite suppressing medicines reduce the volume of food carrying your nutrition.

The second is physical activity, and specifically resistance training. Losing weight in a deficit costs some muscle, and muscle contributes to how many calories you burn at rest. Protecting it is what makes a result hold after treatment ends.

The third is behavioural support. NICE frames weight management as multicomponent for a reason: the medicine changes appetite, but the service should also support a healthy lifestyle, including sleep, mental health, and the reasons people eat when they are not hungry.

The fourth is monitoring, which means someone reviewing your progress, your side effects and your other medicines at intervals rather than only at the start.

If a service supplies a medicine with none of that attached, you are buying a prescription rather than receiving weight management. The distinction shows up most clearly a year later, when treatment ends and only the habits remain.

Can you get anti-obesity medication over the counter?

Almost never. Every licensed anti-obesity medicine in the UK is a prescription only medicine, with a single exception.

That exception is a lower strength orlistat, which is classified as a pharmacy medicine. It is kept behind the counter and sold following a short assessment by a pharmacist, to men aged 18 and over meeting a minimum BMI. It is not on the shelf, and you cannot buy it without that conversation.

The distinction between a pharmacy medicine and a general sale medicine is worth knowing, because it is often blurred online. A pharmacy medicine still involves a healthcare professional deciding it is appropriate for you.

Everything else you can buy freely, whether in a shop or online, is a food supplement rather than a medicine. Food supplements are regulated as food and are not assessed for effectiveness before sale. Some marketed as fat burners have been found to contain undeclared pharmaceutical ingredients.

The MHRA has repeatedly warned about illegally supplied slimming products sold online, including those containing 2,4-dinitrophenol, known as DNP, an industrial chemical that has caused deaths in the UK. If a product is not a licensed medicine supplied by a registered pharmacy, treat it as unsafe.

Why obesity is treated as a long term condition

Anti-obesity medicines treat obesity while they are being taken, in the same way that blood pressure medicines lower blood pressure while they are being taken. Stopping generally means the condition returns.

The evidence for this is unusually clear. In the STEP 1 trial, 1,961 men aged 18 and over with obesity, or with overweight plus at least one weight related condition, received once weekly semaglutide or placebo alongside lifestyle support for 68 weeks. Mean weight change at 68 weeks was 14.9% with semaglutide compared with 2.4% with placebo, with wide variation between individuals. An extension followed a subset of participants for a year after treatment stopped, and they regained around two thirds of the weight they had lost.

That finding is more useful than the headline percentage. It tells you that these are treatments for an ongoing condition rather than a course with an end date, and it explains why the behavioural component matters so much. What you build while on treatment is what remains available to you if treatment ends.

Results vary between individuals.

Side effects and safety

Every anti-obesity medicine and other weight loss drugs has side effects, and while serious health problems are rare, they are still important to review before prescribing; the pattern of risk differs by class rather than being generic.

The GLP-1 receptor agonists and the dual receptor agonist commonly cause nausea, vomiting, diarrhoea or constipation, usually worst in the early weeks and after each dose increase. These generally settle. Less common but more serious problems include gallbladder problems and pancreatitis, and severe or persistent abdominal pain needs prompt assessment rather than waiting. Oral semaglutide also has specific administration instructions: it should be taken on an empty stomach and you should wait before eating or drinking, because absorption can otherwise be affected. Because they slow stomach emptying, they can also affect absorption of other oral medicines.

Orlistat causes digestive effects tied directly to how much fat you eat, including urgent bowel movements, oily stools and wind. It also reduces absorption of the fat soluble vitamins A, D, E and K, which is why product information advises a multivitamin containing them, separated in time from the medicine.

The naltrexone and bupropion combination carries more interactions than the others, because both ingredients are used elsewhere in medicine. Opioid medicines, a history of seizures, uncontrolled high blood pressure and eating disorders all require particularly careful assessment. Common side effects can include nausea, constipation, and headache. Other prescription medicines used in obesity care, such as phentermine in markets where it is available, may cause insomnia and increased heart rate.

Who is not suitable

Speak to a qualified healthcare professional before starting or seeking any of these treatments if you are pregnant, breastfeeding or planning pregnancy, are under 18, have a current or previous eating disorder, take insulin or other medicines that lower blood glucose, have a history of pancreatitis or gallstones, have had bariatric surgery, have a personal or family history or family history of conditions that may affect suitability, or take medicines that require consistent food intake.

Some medicines also need extra caution or may be unsuitable in people with coronary artery disease, those taking monoamine oxidase inhibitors, or those being assessed in a specialist weight management service after weight loss surgery or with severe obesity.

NICE guidance on prescribing these medicines specifically does not cover prescribing in pregnancy, which reflects how clearly they are not appropriate then.

When to seek medical advice

Speak to a healthcare professional if:

• You have severe or persistent abdominal pain while taking an anti-obesity medicine
• You have persistent vomiting or cannot keep fluids down
• You develop yellowing of the skin or eyes
• You have taken a product bought outside a registered pharmacy and feel unwell
• You take other prescribed medicines and are starting or stopping weight management treatment
• You are considering stopping treatment, so it can be planned rather than abrupt
• Your relationship with food or your body has started to feel distressing

Where a clinical assessment fits

If you are researching anti-obesity medication because you are considering treatment, the useful next step is an assessment rather than a purchase.

An online consultation with UK registered prescribers covers your medical history, current medicines, BMI and any weight related conditions, and reviews whether weight loss medications are appropriate, which anti-obesity prescription medications may help you lose weight safely, and what review points apply before anything is supplied.

Treatment suitability depends on an individual clinical assessment, and your prescriber will determine the appropriate treatment.

Medical Disclaimer

This article is for general information and does not replace individual medical advice. It does not diagnose any condition, recommend a specific treatment for you, or compare or rank medicines against one another.

Treatment suitability depends on an individual clinical assessment by an appropriately qualified prescriber, who will consider your medical history and current medicines. Prescription medicines should only be used under the supervision of an appropriately qualified prescriber, and never take one that was not prescribed for you. If you miss a dose, follow the patient information leaflet supplied with the medicine, and do not take a double dose to make up for it. Report suspected side effects through the MHRA Yellow Card scheme.

Results vary between individuals. If you have any of the warning signs above, seek medical advice.